NASDAQ:LXRX Lexicon Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.52 +0.07 (+4.83 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$1.43Now: $1.52▼$1.5350-Day Range$1.45MA: $1.71▼$1.9352-Week Range$1.43Now: $1.52▼$5.33Volume739,759 shsAverage Volume1.21 million shsMarket Capitalization$162.80 millionP/E Ratio8.00Dividend YieldN/ABeta1.34 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.55, Lexicon Pharmaceuticals has a forecasted upside of 67.8% from its current price of $1.52.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesLexicon Pharmaceuticals has received 450 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLexicon Pharmaceuticals has received 446 “underperform” votes. (Add your “underperform” vote.)Community SentimentLexicon Pharmaceuticals has received 50.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote “Outperform” if you believe LXRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Lexicon Pharmaceuticals is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($1.66) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is 8.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.34.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is 8.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.61.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CUSIP52887210 CIK1062822 Webwww.lexpharma.com Phone281-863-3000Debt Debt-to-Equity Ratio4.28 Current Ratio2.52 Quick Ratio2.48Price-To-Earnings Trailing P/E Ratio8.00 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$322.07 million Price / Sales0.51 Cash Flow$1.65 per share Price / Cash Flow0.92 Book Value$1.10 per share Price / Book1.38Profitability EPS (Most Recent Fiscal Year)$1.35 Net Income$130.13 million Net Margins12.26% Return on Equity50.16% Return on Assets10.51%Miscellaneous Employees202 Outstanding Shares107,106,000Market Cap$162.80 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $1.52 +0.07 (+4.83 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive LXRX News and Ratings via Email Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions How has Lexicon Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)? Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LXRX stock has decreased by 33.0% and is now trading at $1.52. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Lexicon Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Lexicon Pharmaceuticals. When is Lexicon Pharmaceuticals' next earnings date? Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Lexicon Pharmaceuticals. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.02. The biopharmaceutical company had revenue of $9.16 million for the quarter, compared to the consensus estimate of $8.70 million. Lexicon Pharmaceuticals had a net margin of 12.26% and a return on equity of 50.16%. View Lexicon Pharmaceuticals' earnings history. What price target have analysts set for LXRX? 5 brokers have issued 1 year price objectives for Lexicon Pharmaceuticals' shares. Their forecasts range from $2.10 to $3.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $2.55 in the next twelve months. This suggests a possible upside of 67.8% from the stock's current price. View analysts' price targets for Lexicon Pharmaceuticals. Are investors shorting Lexicon Pharmaceuticals? Lexicon Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totaling 11,830,000 shares, a decline of 13.0% from the August 31st total of 13,590,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the days-to-cover ratio is presently 7.1 days. Approximately 11.5% of the company's shares are sold short. View Lexicon Pharmaceuticals' Short Interest. Who are some of Lexicon Pharmaceuticals' key competitors? Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX) and Repligen (RGEN). View all competitors. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), Dynavax Technologies (DVAX), ACADIA Pharmaceuticals (ACAD), MannKind (MNKD), Gilead Sciences (GILD), Geron (GERN), Opko Health (OPK), Micron Technology (MU) and TherapeuticsMD (TXMD). Who are Lexicon Pharmaceuticals' key executives? Lexicon Pharmaceuticals' management team includes the following people: Mr. Lonnel Coats, Pres, CEO & Director (Age 54)Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)Dr. Praveen Tyle, Exec. VP of R&D (Age 59)Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60) What is Lexicon Pharmaceuticals' stock symbol? Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX." Who are Lexicon Pharmaceuticals' major shareholders? Lexicon Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (10.29%), Federated Hermes Inc. (1.60%), AQR Capital Management LLC (1.13%), Marshall Wace LLP (0.87%), Bank of New York Mellon Corp (0.53%) and Goldman Sachs Group Inc. (0.48%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker. View institutional ownership trends for Lexicon Pharmaceuticals. Which institutional investors are selling Lexicon Pharmaceuticals stock? LXRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, AQR Capital Management LLC, Jacobs Levy Equity Management Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for Lexicon Pharmaceuticals. Which institutional investors are buying Lexicon Pharmaceuticals stock? LXRX stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Goldman Sachs Group Inc., WINTON GROUP Ltd, Sei Investments Co., Bridgeway Capital Management Inc., Envestnet Asset Management Inc., Strs Ohio, and Virtu Financial LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker. View insider buying and selling activity for Lexicon Pharmaceuticals. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Lexicon Pharmaceuticals' stock price today? One share of LXRX stock can currently be purchased for approximately $1.52. How big of a company is Lexicon Pharmaceuticals? Lexicon Pharmaceuticals has a market capitalization of $162.80 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe. What is Lexicon Pharmaceuticals' official website? The official website for Lexicon Pharmaceuticals is www.lexpharma.com. How can I contact Lexicon Pharmaceuticals? Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000. This page was last updated on 9/27/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
